LAGUNA HILLS, Calif. / Sep 26, 2023 / Business Wire / Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo’s Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company.
The awards were granted under Sonendo’s 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08.
The restricted stock unit awards vest over a four-year period, with twenty five percent of the shares underlying each award vesting on the anniversary of the award’s vesting commencement date, September 25, 2023, and six and one-quarter percent of the shares underlying each award vesting quarterly thereafter, subject to continued service. The restricted stock units are subject to the terms and conditions of the Inducement Award Plan.
About Sonendo
Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. Sonendo is also the parent company of TDO Software, the developer of widely used endodontic practice management software solutions, designed to simplify practice workflow. TDO Software integrates practice management, imaging, referral reporting and CBCT imaging, and offers built-in communication with the GentleWave System.
For more information on Sonendo, visit www.sonendo.com. For more information on the GentleWave System, visit www.gentlewave.com/doctor.
Last Trade: | US$1.20 |
Daily Volume: | 0 |
Market Cap: | US$502K |
November 08, 2023 October 17, 2023 September 28, 2023 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load